Gastrobody Therapeutics is developing ultrastable, orally-administered protein therapeutics to treat conditions of the gastrointestinal (GI) tract.

Traditional antibody therapeutics against GI tract diseases, such as Crohn’s disease and ulcerative colitis, must be injected. This systemic administration can lead to loss of efficacy and severe side-effects. Our gastrobodies target the GI tract locally, not via the bloodstream, offering a  patient-centric approach to treat not only IBD but a variety of GI tract diseases.

Gastrobodies have the potential to be a transformative therapeutic platform against GI tract diseases by leveraging their specificity to the target and their unique ability to survive the harsh conditions within the GI tract.